
TB policies in Eastern Europe and Central Asia (EECA)

Step Up for TB2020 Tuberculosis Policies in 37 Countries A survey of prevention, testing, and treatment policies and practices



Internationally recommended key policies uptake








To read the full *Step Up for TB 2020* report with results for all 37 countries, visit stoptb.org/SUFT and msfaccess.org/stepupfortb

Key numbers in 2019*





(nr.)











treatment coverage (%)

UNHLM TB treatment target for 2019 achieved (%)

UNHLM DR-TB treatment target for 2019 achieved (%)

UNHLM childhood TB treatment target for 2019 achieved (%)

UNHLM prevention therapy target for 2019 achieved (%)

Key TB policies dashboard

National policies indicate	Azerbaijan	Belarus	Kazakhstan	Kyrgyzstan	R. Moldova	Russian Fed.	Tajikistan	Ukraine	Uzbekistan
Diagnosing TB									
a rapid molecular diagnostic (RMD) as the initial test for TB									
urinary TB LAM for routine diagnosis of TB in people living with HIV (PLHIV) and the test is routinely used in both inpatient (IPD) and outpatient (OPD) settings**									
RIF and INH resistance testing for all people starting on treatment; at least FLQ resistance testing for all people with RR-TB; and DST methods available in country for RIF, INH, FLQs, Bdq, DIm, Lzd, and Cfz, when these medicines are used for routine treatment ¹									
Treating TB and Models of Care									
decentralised DR-TB treatment to primary healthcare (PHC) facility and at home 2,**									
routine use of injectable-free regimens for children with uncomplicated DR-TB									
use of a modified shorter all-oral regimen for eligible adults with DR-TB, either for routine use or operational research ³									
no limitation to the routine, 4 combined use of Bdq and Dlm 5 beyond 6 months **						N/A***			
Preventing TB									
a shorter TB preventive treatment (TPT) regimen (3HP, 3RH, 4R or 1HP) ⁶									
household contacts of a person with bacteriologically confirmed DS-TB and DR-TB are investigated for signs and symptoms of TB**									
PLHIV are eligible for TPT									
household contacts of a person with bacteriologically confirmed DS-TB are eligible for TPT, regardless of age**									
Procuring Medicines for TB									
Country is enrolled in the WHO Collaborative Registration Procedure (CRP) ⁷									
Stringent regulatory authority (SRA) ⁸ approval and/or WHO Prequalification (PQ) ⁹ required for importation of TB medicines purchased with domestic funding									
SRA and/or WHO PQ quality-assured product status required for procurement of locally manufactured TB medicines	N/A****			N/A****			N/A****		N/A****

LEGEND Is this policy in place at the regional level?

📕 Yes 📃 Partial 📕 No 📃 No data

N/A - Not applicable

(*) Source: WHO and Stop TB Partnership (accessed 2020 Oct.). (**) This data consists of two or more individual indicators. "No data" is used when there is "no data" for one or more of the individual indicators considered. (***) Bdq and/or DIm are not indicated in the national policies for routine treatment. (****) TB medicines are not locally manufactured, or locally manufactured TB medicines are not procured. (1) Abbreviations: rifampicin (RIF), isoniazid (INH), fluoroquinolone (FLQ), rifampicin-resistant TB (RR-TB), bedaquiline (Bdq), delamanid (DIm), linezolid (Lzd), clofazamine (Cfz). (2) DR-TB treatment initiation and follow-(1) Appreviations: intempicin (kr), isoniazia (kri), ison



